Kenvue Inc. (NYSE:KVUE) Receives Average Recommendation of “Hold” from Analysts

Shares of Kenvue Inc. (NYSE:KVUE) have earned a consensus recommendation of “Hold” from the sixteen brokerages that are covering the stock, Marketbeat Ratings reports. Thirteen analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $19.3333.

Several research firms recently weighed in on KVUE. Barclays reduced their target price on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 14th. Citigroup cut their price target on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, April 15th. UBS Group cut their price target on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Weiss Ratings restated a “hold (c-)” rating on shares of Kenvue in a research note on Wednesday, April 8th. Finally, Argus upgraded shares of Kenvue to a “hold” rating in a research note on Friday, March 6th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KVUE. Norges Bank bought a new position in Kenvue during the fourth quarter worth about $756,862,000. Independent Franchise Partners LLP grew its stake in Kenvue by 56.3% during the fourth quarter. Independent Franchise Partners LLP now owns 48,146,476 shares of the company’s stock worth $830,527,000 after buying an additional 17,343,785 shares during the last quarter. Sculptor Capital LP grew its stake in Kenvue by 1,023.5% during the fourth quarter. Sculptor Capital LP now owns 12,886,328 shares of the company’s stock worth $222,289,000 after buying an additional 11,739,328 shares during the last quarter. Capitolis Liquid Global Markets LLC grew its stake in Kenvue by 1,116.8% during the fourth quarter. Capitolis Liquid Global Markets LLC now owns 10,950,999 shares of the company’s stock worth $188,905,000 after buying an additional 10,050,999 shares during the last quarter. Finally, Cibc World Markets Corp bought a new stake in Kenvue during the fourth quarter worth about $162,193,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Down 0.8%

NYSE KVUE opened at $17.59 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.96. The firm has a 50-day simple moving average of $17.65 and a 200 day simple moving average of $17.24. Kenvue has a twelve month low of $14.02 and a twelve month high of $24.61. The stock has a market cap of $33.76 billion, a PE ratio of 20.69, a PEG ratio of 4.02 and a beta of 0.55.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.76%. The business had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.84 billion. During the same quarter last year, the company earned $0.24 earnings per share. The firm’s revenue was up 4.5% on a year-over-year basis. On average, research analysts forecast that Kenvue will post 1.1 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th will be paid a dividend of $0.2075 per share. The ex-dividend date is Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.7%. Kenvue’s dividend payout ratio (DPR) is currently 107.79%.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.